Pharma

Your Article Summary

See Latest Articles

Genzyme’s Campath Meets Primary Endpoint in Phase 3 Combination Therapy Trial for Chronic Lymphocytic Leukemia
Genzyme, 09/25/09

Genzyme Corporation announced that its randomized Phase 3 clinical trial investigating Campath in combination with Fludara in relapsed or refractory chronic lymphocytic leukemia patients met its primary endpoint by demonstrating a significant improvement in progression free survival.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09

Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09

Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09

See All of Drug Trials